306 related articles for article (PubMed ID: 2039968)
1. [Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) values in patients with pancreatic cancer or pancreatitis].
Changchine CS; Yung CY; Tzen KY
Changgeng Yi Xue Za Zhi; 1991 Mar; 14(1):32-8. PubMed ID: 2039968
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis.
Shimizu M; Saitoh Y; Ohyanagi H; Itoh H
Arch Pathol Lab Med; 1990 Feb; 114(2):195-200. PubMed ID: 1689141
[TBL] [Abstract][Full Text] [Related]
4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
5. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
[TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic antigen and carbohydrate antigen 19-9 levels of peripheral and draining venous blood in colorectal cancer patients. Correlation with histopathologic and immunohistochemical variables.
Tabuchi Y; Deguchi H; Saitoh Y
Cancer; 1988 Oct; 62(8):1605-13. PubMed ID: 3167774
[TBL] [Abstract][Full Text] [Related]
9. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer.
Fabris C; Basso D; Piccoli A; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Faggian D; Vianello D; Plebani M
J Med; 1991; 22(3):145-56. PubMed ID: 1770322
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of non-invasive diagnostic tests in detecting cancer of the pancreas.
Wang JY; Chen FZ; Yang YZ
Chin Med J (Engl); 1990 Oct; 103(10):817-20. PubMed ID: 2125254
[TBL] [Abstract][Full Text] [Related]
11. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas.
Steinberg WM; Gelfand R; Anderson KK; Glenn J; Kurtzman SH; Sindelar WF; Toskes PP
Gastroenterology; 1986 Feb; 90(2):343-9. PubMed ID: 2416628
[TBL] [Abstract][Full Text] [Related]
13. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer.
Banfi G; Bravi S; Ardemagni A; Zerbi A
Int J Biol Markers; 1996; 11(2):77-81. PubMed ID: 8776607
[TBL] [Abstract][Full Text] [Related]
14. Limits of CEA and ferritin in the diagnosis of pancreatic cancer.
Plebani M; Fabris C; Basso D; Del Favero G; Angonese C; Leandro G; Di Mario F; Burlina A; Naccarato R
Int J Pancreatol; 1988; 3 Suppl 1():S113-7. PubMed ID: 3209864
[TBL] [Abstract][Full Text] [Related]
15. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
[TBL] [Abstract][Full Text] [Related]
16. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
17. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen (CEA) activity in pancreatic juice of patients with pancreatic carcinoma and pancreatitis.
Sharma MP; Gregg JA; Loewenstein MS; McCabe RP; Zamcheck N
Cancer; 1976 Dec; 38(6):2457-61. PubMed ID: 1000475
[TBL] [Abstract][Full Text] [Related]
19. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
Haglund C
Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
[TBL] [Abstract][Full Text] [Related]
20. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
